Video

Dr. Pettaway: 2021 recipient of SUO’s Huggins Medal

Author(s):

Urology Times staff
Conference|SUO Annual Meeting

“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Curtis A. Pettaway, MD, discusses what receiving the Society of Urologic Oncology’s 2021 Huggins Medal meant to him. Pettaway is a professor of urology at the University of Texas MD Anderson Cancer Center in Houston.

      Related Videos
      Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
      Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
      Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tailoring prostate cancer care for older adults
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: New strategies emerge for metastatic prostate cancer
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
      Human kidney stones | Image Credit: © freshidea - stock.adobe.com
      Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
      Alternative treatments and patient communication for genitourinary syndrome of menopause
      Related Content
      Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
      May 5th 2025

      AUA 2025 recap: Urologic oncology trials in progress

      Hannah Clarke
      Take a look through some of the notable studies that were spotlighted during this year’s meeting.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
      May 2nd 2025

      TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

      Hannah Clarke
      Data showed an overall CR rate of 82.4%.
      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
      April 30th 2025

      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

      Amy M. Pearlman, MD Ryan Terlecki, MD
      A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
      April 30th 2025

      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

      Hannah Clarke
      Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      © 2025 MJH Life Sciences

      All rights reserved.